News >

Immunotherapy Combos Emerging in HCC Armamentarium

Caroline Seymour
Published: Tuesday, Feb 18, 2020

Ghassan K. Abou-Alfa, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center

Ghassan K. Abou-Alfa, MD

The treatment arsenal for advanced hepatocellular carcinoma (HCC) is expected to become more robust with PD-1/PD-L1 inhibitor–based combination therapies, according to Ghassan K. Abou-Alfa, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center.
... to read the full story
To Read the Full Story



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x